China's CanSino rises as vaccine gets Canada's clinical trial nod

Cansino Biologics

24/07/2023 07:04

** Hong Kong-listed shares of China's CanSino Biologics Inc
 6185.HK  rise as much as 8.2% to HK$27.20, highest since July
14, and on course for the second session of gains
    ** Stock set for the biggest one-day pct rise since June 26,
if gains hold
    ** Clinical-stage vaccine company says Recombinant Zoster
Vaccine, developed with Vaccitech Ltd, has obtained clinical
trials approval from Health Canada 
    ** Tianjin-based company says the vaccine candidate was able
to stimulate both humoral and cellular immunity and has the
potential to be a product with high efficacy profile
    ** CanSino's Shanghai-listed shares  688185.SS  rise 2.9% 
    ** Hang Seng Commerce & Industry Index  .HSNC  falls 1.5%,
while healthcare index  .HSCIH  climbs 0.3
    ** Hang Seng Composite Index  .HSCI  falls 1.4% and Hang
Seng Index  .HSI  drops 1.6%
    ** As of last close, the Hong Kong-listed stock dropped has
62.3% this year, while Shanghai shares are down 46.6%

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))